TB
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective | Pharmaceutics |  | 2023 | 41 | 6 | ||
| From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure | Pharmaceutics | | 2023 | 50 | 7 | ||
| Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation | The journal of antimicrobial chemotherapy |  | 2022 | 60 | 0 | ||
| Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study | Multiple Sclerosis Journal | | 2021 | 243 | 0 | ||
| The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib | Frontiers in Pharmacology | | 2020 | 296 | 146 | ||
| Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review | Therapeutic Drug Monitoring | | 2020 | 199 | 1 | ||
| Validation and Clinical Application of a Multiplex High Performance Liquid Chromatography - Tandem Mass Spectrometry Assay for the Monitoring of Plasma Concentrations of 12 Antibiotics in Patients with Severe Bacterial Infections | Journal of Chromatography. B | | 2020 | 242 | 85 | ||
| Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry | Journal of Chromatography. B | | 2018 | 214 | 0 | ||
| Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring | Journal of Pharmaceutical and Biomedical Analysis | | 2018 | 200 | 2 | ||
| Guidance to develop individual dose recommendations for patients on chronic hemodialysis | Expert Review of Clinical Pharmacology | 2017 | 473 | 0 | |||
| Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid | Dermatology | | 2017 | 391 | 0 | ||
| In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid | Drug Metabolism and Disposition | | 2016 | 507 | 218 | ||
| Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial | Cancer chemotherapy and pharmacology | | 2014 | 467 | 0 | ||
| Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals | Pharmacogenetics and genomics | | 2013 | 558 | 0 | ||
| Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women | Antiviral therapy | | 2013 | 530 | 0 | ||
| Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia | AIDS | | 2012 | 625 | 0 | ||
| Pharmacovigilance in pregnancy: adverse drug reactions associated with fetal disorders | Journal of perinatal medicine | | 2012 | 677 | 1 331 | ||
| Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma | The Journal of clinical endocrinology and metabolism | | 2012 | 631 | 0 | ||
| ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir | Pharmacogenetics and genomics | | 2010 | 608 | 0 | ||
| Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir | Antimicrobial agents and chemotherapy | | 2009 | 569 | 0 | ||
| Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals | Clinical pharmacology and therapeutics | | 2009 | 600 | 0 |
